Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
AstraZeneca
Novartis
QuintilesIMS
Johnson and Johnson
Baxter
McKesson
Boehringer Ingelheim
Julphar
Healthtrust

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,945,063

« Back to Dashboard

Which drugs does patent 8,945,063 protect, and when does it expire?

Patent 8,945,063 protects OTREXUP and is included in one NDA.

This patent has twelve patent family members in seven countries.
Summary for Patent: 8,945,063
Title:Hazardous agent injection system
Abstract: Injection systems comprising a powered injector and one or more hazardous agents are disclosed.
Inventor(s): Wotton; Paul K. (Newton, PA), Sadowski; Peter L. (Woodbury, MN), Hayes; John William (Chaska, MN)
Assignee: Antares Pharma, Inc. (Ewing, NJ)
Application Number:14/158,289
Patent Claim Types:
see list of patent claims
Formulation; Dosage form; Use;

Drugs Protected by US Patent 8,945,063

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-005 Nov 7, 2014 DISCN No No ➤ Subscribe ➤ Subscribe Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-001 Oct 11, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-006 Mar 24, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-002 Oct 11, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-007 Mar 24, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-003 Oct 11, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-008 Mar 24, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-004 Oct 11, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,945,063

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,480,631 Hazardous agent injection system ➤ Subscribe
8,579,865 Hazardous agent injection system ➤ Subscribe
9,421,333 Hazardous agent injection system ➤ Subscribe
9,750,881 Hazardous agent injection system ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,945,063

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea 101597672 ➤ Subscribe
South Korea 20120028294 ➤ Subscribe
Japan 2016104214 ➤ Subscribe
Japan 5968976 ➤ Subscribe
Japan 2015042270 ➤ Subscribe
Japan 5732039 ➤ Subscribe
Japan 2012521224 ➤ Subscribe
European Patent Office 2408493 ➤ Subscribe
China 102612381 ➤ Subscribe
Canada 2755779 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Farmers Insurance
Merck
Healthtrust
Daiichi Sankyo
Chinese Patent Office
UBS
Cipla
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot